Compounds > arg-pro-hyp-gly-thi-ser-phe-thi-arg tfa
Page last updated: 2024-09-03

arg-pro-hyp-gly-thi-ser-phe-thi-arg tfa and icatibant

arg-pro-hyp-gly-thi-ser-phe-thi-arg tfa has been researched along with icatibant in 1 studies

Compound Research Comparison

Studies
(arg-pro-hyp-gly-thi-ser-phe-thi-arg tfa)		Trials
(arg-pro-hyp-gly-thi-ser-phe-thi-arg tfa)		Recent Studies (post-2010)
(arg-pro-hyp-gly-thi-ser-phe-thi-arg tfa)		Studies
(icatibant)		Trials
(icatibant)		Recent Studies (post-2010) (icatibant)
11001,13749259

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bao, G; Gohlke, P; Qadri, F; Stauss, B; Stauss, H; Unger, T1

Other Studies

1 other study(ies) available for arg-pro-hyp-gly-thi-ser-phe-thi-arg tfa and icatibant

ArticleYear
HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats.
    European journal of pharmacology, 1991, Jul-23, Volume: 200, Issue:1

    Topics: Amino Acid Sequence; Animals; Bradykinin; Catecholamines; Fluoroacetates; Half-Life; Male; Molecular Sequence Data; Oligopeptides; Rats; Rats, Inbred Strains

1991